ID   PC-3/DTX
AC   CVCL_A2FD
DR   cancercelllines; CVCL_A2FD
DR   Wikidata; Q105510544
RX   PubMed=32968452;
CC   Population: Caucasian.
CC   Doubling time: 28.87 +- 0.75 hours (PubMed=32968452).
CC   Selected for resistance to: ChEBI; CHEBI:4672; Docetaxel anhydrous (Taxotere).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Bone; UBERON=UBERON_0002481.
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0035 ! PC-3
SX   Male
AG   62Y
CA   Cancer cell line
DT   Created: 12-01-21; Last updated: 05-10-23; Version: 5
//
RX   PubMed=32968452; DOI=10.3892/ol.2020.12093;
RA   Liu J., Huang Y.-J., Zhu D.-Y., Dai Y., Liu D., Zhai Y., Liang X.-G.,
RA   Wu L.-H., Zhao Q.-W.;
RT   "Establishment and characterization of a docetaxel-resistant human
RT   prostate cancer cell line.";
RL   Oncol. Lett. 20:230.1-230.7(2020).
//